Please assess the completion status of the following clinical trial:

Trial Title: ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 ≤ 75~2. Progressive disease on or after anti-PD-1/anti-PD-L1 monotherapy or progressive disease on or after anti PD-1 plus anti-CTLA-4 therapy~3. The patient has histologically confirmed metastatic melanoma~4. HLA-A2 positive~5. At least one measurable parameter according to RECIST version 1.1 guidelines~6. ECOG performance status of 0 or 1~7. No significant toxicity from previous cancer treatments (CTC ≤ 1)~8. Women of childbearing potential: Negative serum pregnancy test and must use effective contraception. This applies from screening and until 6 months after treatment. Birth control pills, spiral, depot injection with gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot patch are all considered effective contraceptives~9. Men with female partner of childbearing potential must use effective contraception from screening and until 6 months after treatment. Effective contraceptives are as described above for the female partner. In addition, documented vasectomy and sterility or double barrier contraception are considered effective contraceptives~10. Signed statement of consent after receiving oral and written study information~11. Willingness to participate in the planned treatment and follow-up and capable of handling~12. The patient has met the following haematological and biochemical criteria:~    1. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases~   2. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN~   3. Serum creatinine ≤1,5 X ULN~   4. ANC (Absolute Neutrophil Count) ≥1,000/mcL~   5. Platelets ≥ 75,000 /mcL~   6. Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L~Exclusion Criteria:~1. Another malignancy or concurrent malignancy unless disease-free for 3 years~2. Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to screening~3. Prior treatment with adoptive transfer of Tumor Infiltrating T cells (TIL)~4. Grade 3-4 adverse events upon treatment with PD-1 checkpoint inhibitors (only phase B)~5. The patient has CNS metastases and/or carcinomatous meningitis~6. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)~7. The patient is pregnant or breastfeeding~8. The patient has an active infection requiring systemic therapy~9. The patient has received a live virus vaccine within 30 days of planned start of therapy~10. Significant medical disorder according to investigator; e.g severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus.~11. Concurrent treatment with other experimental drugs~12. Any significant active autoimmune disease~13. Severe allergy or anaphylactic reactions earlier in life~14. Known hypersensitivity to one of the active drugs or one or more of the excipients.~15. Unrelieved lower urinary tract obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: OTHER): Six patients will be included in Part A. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v. on day -4, -3) followed by i.v. infusion of the MASE-T product on day 0.
- Part B (Type: OTHER): Six patients will be includede in Part B. After inclusion 300 mL blood will be drawn from the patients for the production of the MASE-T cell product. Four days prior to MASE-T infusion the patient will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m2/day i.v. on day -4, -3, -2 and fludarabine 30 mg/m2/day i.v on day -4, -3) followed by i.v infusion of the MASE-T product on day 0. Pembrolizumab 2 mg/kg will be administered on day -1 and day +21.

Based on this trial design, predict the completion outcome and termination type (if applicable).